XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Stephan Meinke as Head of R&D
Dr. Meinke received his doctorate degree in 2010 from the University of Heidelberg, Germany, for his work on natural killer (NK) cell signaling. Since then, he has worked as a researcher at Karolinska Institutet and the Karolinska University Hospital with a research focus on NK cell biology and transfusion immunology. He currently holds a position as assistant professor in the Cell and Gene Therapy Group, HERM, Department of Medicine, at Karolinska Institutet.
“Stephan has a strong background in the field of NK cell biology and will be a key asset for XNK as we push our technology platform forward,” says Johan Liwing, CEO of XNK Therapeutics.
For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit xnktherapeutics.com.
About XNK Therapeutics’s technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen. The assets of XNK Therapeutics are protected by patents in the US, Europe and certain other jurisdictions. Additional patent applications have been filed
